Literature DB >> 20139823

F-18 FDG PET/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study.

Nghi C Nguyen1, Isaac Tran, Christopher N Hueser, Dana Oliver, Hussein R Farghaly, Medhat M Osman.   

Abstract

PURPOSE: The current study characterized pleural changes induced by talc pleurodesis (TP), based on serial positron emission tomography/computer-tomography (PET/CT) with F-18 fluorodeoxyglucose (FDG).
MATERIALS AND METHODS: A total of 8 cancer patients who had both TP and PET/CT and no evidence of active pleural involvement after TP were retrospectively evaluated. Maximum standard uptake values, maximum Hounsfield units (HU), and thickness were followed over time.
RESULTS: The 8 patients had 25 PET/CT scans performed in an average of 22 months after TP. An increased FDG uptake was associated with an increase in pleural thickness within 5 months after TP, and both parameters showed statistical significance as compared with findings before TP. After 5 months of TP, the standard uptake value appeared to persist or increase further, and the pleural thickening stabilized. The formation of calcification was a slow process and might lag behind the changes in FDG metabolism and pleural thickness. The HU did not change significantly once pleural calcification had been formed.
CONCLUSIONS: Knowledge of aforementioned pleural changes may help differentiate TP induced pleural inflammation from pleural malignancy and to avoid false-positive interpretation of FDG PET/CT exams.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20139823     DOI: 10.1097/RLU.0b013e3181bece11

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  14 in total

Review 1.  Malignant pleural mesothelioma: predictors and staging.

Authors:  William G Richards
Journal:  Ann Transl Med       Date:  2017-06

2.  Letters to the Editor.

Authors: 
Journal:  Ochsner J       Date:  2017

3.  Letter to the Editor: Positron Emission Tomography-Positive Pleural-Based Nodule Following Talc Pleurodesis.

Authors:  Rajany Dy; Sumit Patel; Pichapong Tunsupon; M Jeffery Mador
Journal:  Ochsner J       Date:  2017

4.  Integration of PET/CT in Current Diagnostic and Response Evaluation Methods in Patients with Tuberculosis.

Authors:  Ozlem Ozmen; Atila Gökçek; Ebru Tatcı; Inci Biner; Behiye Akkalyoncu
Journal:  Nucl Med Mol Imaging       Date:  2013-09-27

5.  Talc Pleurodesis With Intense 18F-FDG Activity But No 68Ga-DOTA-TATE Activity on PET/CT.

Authors:  Georgios Z Papadakis; Corina Millo; Ulas Bagci; Nicholas J Patronas; Constantine A Stratakis
Journal:  Clin Nucl Med       Date:  2015-10       Impact factor: 7.794

6.  Persistent Inflammation in Pulmonary Granuloma 48 Years after Talcage Pleurodesis, Detected by FDG-PET/CT.

Authors:  J C Fanggiday; R W Rouse; S M Collard; M J de Haas; J M H de Klerk
Journal:  Case Rep Med       Date:  2012-11-06

Review 7.  Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

8.  FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy.

Authors:  Giovenzio Genestreti; Andrea Moretti; Sara Piciucchi; Noemi Giovannini; Riccardo Galassi; Emanuela Scarpi; Marco Angelo Burgio; Dino Amadori; Stefano Sanna; Venerino Poletti; Federica Matteucci; Giampaolo Gavelli
Journal:  J Cancer       Date:  2012-06-01       Impact factor: 4.207

9.  Potential Pitfall in the Assessment of Lung Cancer with FDG-PET/CT: Talc Pleurodesis Causes Intrathoracic Nodal FDG Avidity.

Authors:  Yingbing Wang; Brett W Carter; Victorine Muse; Subba Digumarthy; Jo-Anne Shepard; Amita Sharma
Journal:  Lung Cancer Int       Date:  2013-05-25

10.  Interpretation of PET/CT findings in patients with advanced lung cancer who have undergone pleurodesis.

Authors:  Marcus Paulo Fernandes Amarante; Riad Naim Younes; Letícia Rigo; Marcelo Rocha de Sousa Cruz
Journal:  Ecancermedicalscience       Date:  2014-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.